An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Trial Overview

Am I Eligible?

Participating US Centers

University of Kansas Cancer Center

This center is currently accepting patients.

Kansas City, KS


Oregon Health and Science University (OHSU)
Knight Cancer Institute

This center is currently accepting patients.

Portland, OR


Indiana University Health

This center is currently accepting patients.

Indianapolis, IN


Cancer Institute of Florida

This center is currently accepting patients.

Orlando, FL


Nebraska Cancer Specialists (Omaha)

This center is currently accepting patients.

Omaha, NE

ACCEPTING

This trial is currently open and accepting patients.



Additional Information
Trial Phase

Phase 1/2

Trial Enrollment

60 sparks required

Trial Sponsors
  • Bristol-Myers Squibb
Trial Identifiers

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;